Allogene疗法 ALLO 深 沪
等待开盘 06-30 09:30:00 美东时间
2.22
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 2.22
- 总市值 7.66亿
- 52周最高 4.46
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.9842
- 委 比 0.00%
- 总股本 3.45亿
- 历史最高 55.00
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.8621
- 每 手 1
- 风险率 0.50%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Allogene Launches ATM Offering to Bolster Capital Flexibility
Allogene Therapeutics ( ($ALLO) ) has issued an update. At its June 18, 2026 an...
06-23 04:54
TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation
TScan Therapeutics reported positive interim data from Cohort C of its ALLOHA™ Phase 1 study for TSC-101, a TCR-T therapy for preventing relapse in patients with hematologic malignancies after allo-HCT. Of 14 patients who received TSC-101, 11 achieved complete donor chimerism within three weeks, and two additional patients showed improving chimerism. The therapy was well-tolerated, with safety consistent with post-HCT adverse events. The company ...
06-22 11:00
Cellectis Gains FDA RMAT Status for Allogeneic CAR-T lasme-cel in r/r B-ALL
An announcement from Cellectis SA ( ($CLLS) ) is now available. On June 9, 2026...
06-10 05:09
Artiva Biotherapeutics Announces Clinical, Safety And Translational Data For AlloNK, Its Allogeneic, Non-Genetically Modified Natural Killer Cell Therapy Candidate
Multiple EULAR presentations reinforce potential of AlloNK to drive deep B-cell depletion and meaningful clinical responses across refractory rheumatoid arthritis, Sjögren disease and systemic
06-08 18:34
Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today
Artiva Biotherapeutics highlighted promising clinical and safety data for AlloNK, an allogeneic NK cell therapy, in treating refractory autoimmune diseases at the EULAR 2026 Congress. AlloNK, combined with rituximab, showed robust responses across 31 patients with rheumatoid arthritis (RA), Sjögren disease (SjD), and systemic sclerosis (SSc). RA data demonstrated a 71% ACR50 response at six months in a Phase 2a trial, with durable responses in hi...
06-08 10:30
Allogene Therapeutics names Zachary Roberts CEO in planned succession
Allogene Therapeutics (ALLO) said on Thursday that CEO David Chang will step down effective June 30 after eight years leading the company and will remain on its board of directors. The company named Z...
05-29 05:29
Allogene Therapeutics Announces Planned CEO Succession
Allogene Therapeutics announced that Dr. David Chang will transition from CEO to continue serving on the Board of Directors. Dr. Zachary Roberts, currently EVP, R&D and CMO, will succeed him as President and CEO effective July 1, 2026. Dr. Chang's leadership established Allogene as a leader in allogeneic CAR T therapies, advancing innovative treatments and infrastructure. Dr. Roberts has reshaped the company's clinical strategy, driving advanceme...
05-28 21:02
Artiva Biotherapeutics Announces Data Presentations On Allogenic NK Cell Therapy June 3-6
Abstracts:LB0003Oral PresentationAB-101, an Outpatient-Administered Allogeneic NK Cell Therapy Combined with Rituximab, Generates Robust Clinical Efficacy Responses Comparable with Autologous CAR T in 31 Patients with
05-20 04:07
Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cell Therapy in Rheumatologic Diseases
Artiva Biotherapeutics will present data at the EULAR 2026 Congress on their AlloNK therapy combined with rituximab, showing comparable efficacy to CAR T-cell therapy in autoimmune diseases. Highlights include 71% ACR50 response in refractory rheumatoid arthritis, successful treatment of severe Sjögren's disease, deep B-cell depletion, and a favorable safety profile. A live webcast with Dr. Paul Emery will discuss these findings on June 8, 2026.
05-19 20:05
电话会总结 ｜ Allogene(ALLO)2026财年Q1业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Allogene业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **2026年第一季度财务表现：** - **研发费用**：3200万美元，其中包含270万美元非现金股权激励费用 - **管理费用**：1410万美元，其中包含560万美元非现金股权激励费用 - **净亏损**：4260万美元，合每股亏损0.18美元 - **非现金股权激励总费用**：830万美元 - **现金及现金等价物**：截至3月31日为2.669亿美元 - **融资收入**：4月份通过公开发行获得约2.004亿美元总收入 ## 2. 财务指标变化 **费用指导上
05-14 12:10
